SCHEMBL29310239

SCHEMBL29310239

Cc1cc(Nc2ncc(C#N)c(Nc3cccc(N4CCCC4=O)n3)n2)cc2c1CCN(C)C2

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 2/20 0.42
▸ BTK Q06187 1/20 0.42
▸ WEE1 P30291 6/20 0.41
▸ SYK P43405 1/20 0.38
▸ PLK1 P53350 1/20 0.38
▸ LRRK2 Q5S007 1/20 0.38
▸ MAP4K1 Q92918 2/20 0.38
▸ PKMYT1 Q99640 2/20 0.37
▸ TNK2 Q07912 1/20 0.37
▸ CCNT1 O60563 2/20 0.36
▸ CDK1 P06493 2/20 0.36
▸ CCNB1 P14635 2/20 0.36
▸ CCNA2 P20248 2/20 0.36
▸ CDK2 P24941 2/20 0.36
▸ CDK7 P50613 2/20 0.36
▸ CDK9 P50750 2/20 0.36
▸ CCNH P51946 2/20 0.36
▸ AURKA O14965 1/20 0.36
▸ EGFR P00533 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29310234 0.94 SLC2A1 (0.42) SLC2A1BTKWEE1SYKPLK1
SCHEMBL29310236 0.90 BTK (0.49) SLC2A1BTKWEE1SYKPLK1
SCHEMBL29310230 0.90 WEE1 (0.48) SLC2A1BTKWEE1SYKPLK1
SCHEMBL30997619 0.87 WEE1 (0.43) SLC2A1BTKWEE1SYKPLK1
SCHEMBL29310241 0.87 WEE1 (0.43) SLC2A1BTKWEE1SYKPLK1
SCHEMBL30997652 0.86 WEE1 (0.50) SLC2A1BTKWEE1SYKMAP4K1
SCHEMBL29310246 0.86 WEE1 (0.50) SLC2A1BTKWEE1SYKMAP4K1
SCHEMBL24773973 0.86 SLC2A1 (0.46) SLC2A1BTKWEE1SYKLRRK2
SCHEMBL30997635 0.85 WEE1 (0.49) SLC2A1WEE1SYKPKMYT1TNK2
SCHEMBL29310208 0.85 WEE1 (0.49) SLC2A1WEE1SYKPKMYT1TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B SLC2A1 4591/4885BTK 2297/4885WEE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback